The Readout Loud

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Tämä podcast on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi podcastin jaksot saattavat sisältää mainontaa.

Jaksot(417)

Episode 64: Feuding professors, failing businesses, and journalism 101

Episode 64: Feuding professors, failing businesses, and journalism 101

Who's guilty of "clickbait"? Are spit tubes a bad business? And why are academics emulating Pusha T?

30 Touko 201923min

Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer

Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer

What should you watch for at the year's biggest cancer conference? Why are people having 23andMe-induced identity crises? And what's it like to be at once a journalist and a cancer patient?

23 Touko 201931min

Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials

Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials

Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for that?

16 Touko 201923min

Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

Are law-breaking pharma executives the new mob bosses? Can genome editing preventing heart attacks? And can the FDA regulate drug prices?

9 Touko 201925min

Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms

Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms

Is Biogen bracing for a fight? What does Jack Daniels have to do with immunotherapy? And will "micro-dosing" light the way to actual therapies?

2 Touko 201922min

Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup

Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup

Who gets to be "influential"? Should you be skeptical of for-profit hospitals? And should George Lucas fire his attorneys?

25 Huhti 201922min

Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print

Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print

Who gets to "play God"? Can old technologies learn new tricks? And what does "drug price" even mean?

18 Huhti 201921min

Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst

Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst

How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?

11 Huhti 201925min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
vallattomat
psykopodiaa-podcast
mimmit-sijoittaa
rss-rahapodi
rss-rahamania
ostan-asuntoja-podcast
rss-oivalluksia-rahasta-elamasta
lakicast
hyva-paha-johtaminen
rss-sami-miettinen-neuvottelija
rss-paasipodi
rss-pinnan-alle
oppimisen-psykologia
pomojen-suusta
rss-karon-grilli
rss-yritys-ja-erehdys
rss-lentopaivakirjat
leadcast
rss-asuntosalkku-kasvussa-podcast